Eli Lilly and Company reported significant financial growth for the fiscal year ending December 31, 2025, with total revenue reaching $65.2 billion, a 45% increase from $45.0 billion in 2024. The company's net income nearly doubled, rising 95% to $20.6 billion, compared to $10.6 billion in the previous year. This surge in revenue was primarily driven by strong sales of its cardiometabolic health products, particularly Mounjaro and Zepbound, which accounted for a substantial portion of the revenue increase. Earnings per share also saw a notable rise, reaching $22.95, up from $11.71 in 2024.
The company experienced a 50% increase in volume sales, although this was partially offset by a 6% decline in realized prices. Mounjaro's revenue alone grew by 99% to $23.0 billion, while Zepbound's revenue surged by 175% to $13.5 billion. Internationally, revenue outside the U.S. also increased by 48%, driven by similar product demand. Eli Lilly's gross margin improved to 83% of revenue, up from 81.3% in 2024, reflecting a favorable product mix and enhanced production efficiency.
Strategically, Eli Lilly has been active in expanding its product pipeline and capabilities through acquisitions and collaborations. In 2025, the company completed several significant acquisitions, including Verve Therapeutics for $549 million and SiteOne Therapeutics for $2.9 billion, aimed at bolstering its research and development efforts in cardiovascular and metabolic diseases. The company also reported ongoing clinical trials for several new products, including orforglipron, which is under regulatory review in multiple markets.
Operationally, Eli Lilly employed approximately 50,000 people by the end of 2025, with around 12,000 dedicated to research and development. The company has also been expanding its manufacturing capabilities, investing heavily in new facilities to meet anticipated demand for its products. As of December 31, 2025, Eli Lilly's cash and cash equivalents increased to $7.3 billion, up from $3.3 billion the previous year, indicating a strong liquidity position to support ongoing operations and strategic initiatives.
Looking ahead, Eli Lilly anticipates continued growth driven by its innovative product offerings and strategic partnerships. However, the company also faces challenges, including pricing pressures from government regulations and competition from generic and biosimilar products. The recent agreements with the U.S. government to lower drug prices for certain medications may impact future revenue, but the company remains optimistic about its ability to navigate these challenges and sustain its growth trajectory.
About ELI LILLY & Co
Eli Lilly and Company is a global pharmaceutical firm focused on discovering, developing, manufacturing, and marketing human medicines. Its core segments include cardiometabolic health, oncology, immunology, and neuroscience, offering products like insulin, diabetes treatments, cancer therapies, and immunomodulators. Serving worldwide markets, Lilly emphasizes innovation, intellectual property protection, and strategic collaborations to deliver value-driven, effective therapies for diverse patient needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.